Beam Therapeutics to Encore Data From BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswireJan 23 20:00

Express News | Beam Therapeutics to Encore Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at 2025 Tandem Meetings of Astct and Cibmtr

BreakingsJan 23 20:00

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Simply Wall StJan 16 20:26

Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75

Futu NewsJan 15 19:33 · Ratings

Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)

TipRanksJan 15 15:10 · Ratings

BofA Securities Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $42

Futu NewsJan 15 01:32 · Ratings